Human IL-23 ELISA Kit

Interleukin-23 (IL-23) is a key pro-inflammatory cytokine that belongs to the IL-12 family, playing a pivotal role in regulating the immune response and mediating chronic inflammatory diseases. Composed of two subunits, the unique p19 subunit and the shared p40 subunit (also part of IL-12), IL-23 exerts its biological functions by binding to a heterodimeric receptor complex consisting of IL-23R and IL-12Rβ1 on the surface of target cells. This binding activates downstream signaling pathways, such as the JAK-STAT pathway, which in turn promotes the differentiation, proliferation, and survival of Th17 cells— a subset of T helper cells that are critical drivers of autoimmune and inflammatory disorders.

In the field of biomedical research, the detection and quantification of IL-23 have become essential for understanding the pathogenesis of various diseases. Epidemiological and clinical studies have highlighted the close association between abnormal IL-23 expression and the development of several chronic conditions. For instance:
Psoriasis: As a chronic, recurrent, inflammatory skin disease affecting over 100 million people worldwide (with approximately 7 million in China alone), psoriasis is strongly linked to IL-23 dysregulation. IL-23 maintains the sustained activation of Th17 cells, which secrete IL-17 and other pro-inflammatory cytokines, leading to excessive proliferation of keratinocytes and the formation of typical psoriatic plaques. Studies have shown that targeting the IL-23 pathway with monoclonal antibodies (e.g., guselkumab, risankizumab) achieves significant clinical efficacy, with PASI 75 (75% reduction in Psoriasis Area and Severity Index) response rates exceeding 80% in long-term trials.
Inflammatory Bowel Disease (IBD): Both Crohn’s Disease (CD) and Ulcerative Colitis (UC), the two main subtypes of IBD, involve IL-23-mediated immune dysregulation. In CD, elevated IL-23 levels in intestinal tissues contribute to the destruction of the intestinal barrier and chronic inflammation. Clinical trials of IL-23 inhibitors (e.g., mirikizumab) have demonstrated promising results, with 45.4% of patients achieving clinical response at week 12 and 38.0% achieving endoscopic response at week 52, significantly higher than placebo groups.
Psoriatic Arthritis (PsA): A chronic inflammatory arthritis associated with psoriasis, PsA is characterized by joint inflammation, pain, and structural damage. IL-23 drives the infiltration of inflammatory cells into joint tissues, exacerbating disease progression. Research has confirmed that inhibiting IL-23 can alleviate joint symptoms and slow down radiographic progression in PsA patients.

Against this backdrop, the demand for reliable, sensitive, and specific tools to detect human IL-23 has grown exponentially. ELISA (Enzyme-Linked Immunosorbent Assay) kits have emerged as the gold standard for in vitro IL-23 quantification due to their high specificity, ease of use, and cost-effectiveness. The Human IL-23 ELISA Kit (Cat. No.: EC-0069) from Alta Diagno Tech is designed to meet this critical research need, enabling accurate detection of IL-23 in various human samples (e.g., serum, plasma, cell culture supernatants) to support studies on inflammatory diseases, immunology, and drug development.